SCHEMBL7197324

SCHEMBL7197324

CCOC(=O)C1CSC(c2cc(OC(C)=O)ccc2OC(C)=O)N1C(C)=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.39
▸ KDM4E B2RXH2 3/20 0.38
▸ TSHR P16473 1/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ KIF11 P52732 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ MITF O75030 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7192631 0.90 POLB (0.42) POLBGAARAB9AALDH1A1KDM4E
SCHEMBL7191146 0.88 POLB (0.46) POLBGAARAB9AALDH1A1KDM4E
SCHEMBL7193369 0.86 POLB (0.57) POLBGAARAB9AALDH1A1KDM4E
SCHEMBL7196787 0.78 POLB (0.46) POLBGAARAB9AALDH1A1KMT2A
SCHEMBL7195907 0.77 ALDH1A1 (0.40) POLBGAARAB9AALDH1A1KMT2A
SCHEMBL7188457 0.76 POLB (0.40) POLBGAARAB9AALDH1A1KDM4E
SCHEMBL7186265 0.75 POLB (0.57) POLBGAARAB9AALDH1A1
SCHEMBL7193645 0.75 POLB (0.51) POLBGAARAB9AALDH1A1
SCHEMBL7196929 0.68 ALDH1A1 (0.40) POLBGAARAB9AALDH1A1KMT2A
SCHEMBL10307908 0.64 KMT2A (0.38) GAAALDH1A1KDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030022923-A1 Methods for treatment of sickle cell anemia MEDINOX, INC. 2003-01-30 — — US disclosed
EP-1173174-A4 METHODS FOR TREATMENT OF SICKLE CELL ANEMIA MEDINOX INC (US) 2002-09-18 — — EP disclosed
US-6355661-B1 STABILITY OF ALDEHYDES AND PROTECTED ALDEHYDES MEDINOX, INC. 2002-03-12 — — US disclosed
EP-1173174-A1 METHODS FOR TREATMENT OF SICKLE CELL ANEMIA Medinox, Inc. (US) 2002-01-23 — — EP disclosed
US-6251927-B1 TREATING SICKLE CELL ANEMIA USING PROTECTED FORMS OF ORGANIC ALDEHYDES MEDINOX, INC. 2001-06-26 — — US disclosed
WO-2000062777-A1 METHODS FOR TREATMENT OF SICKLE CELL ANEMIA MEDINOX, INC. (US) 2000-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022923-A1 Methods for treatment of sickle cell anemia SORD, HBG1, HBG2 POLB 1455/4885GAA 73/4885RAB9A 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback